SPARC, Sun Pharma enter into license agreement for SCD-044, a potential treatment for atopic dermatitis, psoriasis, more

Mumbai: Sun Pharma Advanced Research Company Ltd. and Sun Pharmaceutical Industries Ltd. have announced a worldwide licensing agreement on the development and commercialization of SCD-044 which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis, and other auto-immune disorders. SCD-044 is entering phase 2 clinical trials.

Under terms of the license agreement, Sun Pharma will pay SPARC an upfront payment of US$ 20 million.

SPARC will also be eligible to receive up to US$ 125 million as milestone payments contingent upon the achievement of clinical, regulatory, and sales milestones, as well as tiered royalties on sales. Sun Pharma will be responsible for the development, regulatory filings, manufacturing, and commercialization of the product globally.

"SPARC is committed to progressing its pipeline to address the needs of patients. We are proud to be partnering with a global organization with a footprint in auto-immune disorders" said Anil Raghavan, CEO, SPARC. This agreement with Sun Pharma follows the recent announcement that SPARC has acquired Bioprojet SCR's share of rights to SCD-044.

"The in-licensing of SCD-044 adds to our specialty pipeline of innovative dermatology products. It also demonstrates our commitment to this important segment with significant unmet medical needs. SCD-044 may offer an alternate treatment option for patients in this segment who require systemic treatment and may offer benefits in terms of efficacy and safety over existing oral treatments for this population. SCD-044 has the potential to improve the current oral standard of care." said Dilip Shanghvi, Managing Director, Sun Pharma.

SCD-044 is a novel orally bio-available Sphingosine-1-P (S1P1) receptor agonist for the treatment of inflammatory diseases such as atopic dermatitis and psoriasis. S1P1 receptor agonists are promising for the treatment of autoimmune inflammatory diseases as they cause diminished migration of lymphocytes out of lymphatic tissue. This results in a decrease in circulating lymphocytes, thereby reducing inflammation.

Read also: Sun Pharma: USFDA Classifies Halol Facility As Official Action Indicated